AR114930A1 - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
AR114930A1
AR114930A1 ARP180102544A ARP180102544A AR114930A1 AR 114930 A1 AR114930 A1 AR 114930A1 AR P180102544 A ARP180102544 A AR P180102544A AR P180102544 A ARP180102544 A AR P180102544A AR 114930 A1 AR114930 A1 AR 114930A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
fxr
oral administration
salt
farnesoid
Prior art date
Application number
ARP180102544A
Other languages
English (en)
Inventor
Geoffrey Gogniat
Sonali Bose
Claus Dieter Bischoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR114930A1 publication Critical patent/AR114930A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Abstract

La presente se refiere a una composición farmacéutica para administración oral que comprende un agonista no biliar del receptor farnesoide X (FXR) de ácido 2-[(1R,3R,5S)-3-({5-ciclopropil-3-[2-(trifluorometoxi)fenil]-1,2-oxazol-4-il}metoxi)-8-azabiciclo[3.2.1]octan-8-il]-4-fluoro-1,3-benzotiazol-6-carboxílico, o una sal farmacéuticamente aceptable sal del mismo, y al menos un excipiente lipídico; a una cápsula para administración oral que comprende dicha composición farmacéutica; al uso de dicha composición farmacéutica para el tratamiento de un trastorno o condición mediado por FXR; y a un procedimiento para preparar dicha composición farmacéutica.
ARP180102544A 2017-09-12 2018-09-07 Composición farmacéutica AR114930A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762557298P 2017-09-12 2017-09-12

Publications (1)

Publication Number Publication Date
AR114930A1 true AR114930A1 (es) 2020-11-11

Family

ID=63686041

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102544A AR114930A1 (es) 2017-09-12 2018-09-07 Composición farmacéutica

Country Status (15)

Country Link
US (2) US11207313B2 (es)
EP (1) EP3681485A1 (es)
JP (1) JP2020533297A (es)
KR (1) KR20200052280A (es)
CN (1) CN111093637A (es)
AR (1) AR114930A1 (es)
AU (1) AU2018332191B2 (es)
BR (1) BR112020004663A2 (es)
CA (1) CA3072559A1 (es)
CL (1) CL2020000601A1 (es)
IL (1) IL272419A (es)
MX (1) MX2020002432A (es)
RU (1) RU2020111980A (es)
TW (1) TW201919626A (es)
WO (1) WO2019053581A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104022A1 (zh) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
WO2021104021A1 (zh) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
WO2021233461A1 (zh) * 2020-05-22 2021-11-25 苏州晶云药物科技股份有限公司 苯并噻唑类化合物的新晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
CA2779736A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
HUE054819T2 (hu) 2016-02-22 2021-10-28 Novartis Ag Eljárások FXR agonista alkalmazására
EP3842043A1 (en) 2016-02-22 2021-06-30 Novartis AG Methods for using fxr agonists
ES2902404T3 (es) 2016-02-22 2022-03-28 Novartis Ag Métodos para utilizar agonistas de fxr.
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby

Also Published As

Publication number Publication date
MX2020002432A (es) 2020-07-13
US11207313B2 (en) 2021-12-28
CA3072559A1 (en) 2019-03-21
EP3681485A1 (en) 2020-07-22
KR20200052280A (ko) 2020-05-14
RU2020111980A (ru) 2021-10-13
CL2020000601A1 (es) 2020-09-11
US20190076418A1 (en) 2019-03-14
IL272419A (en) 2020-03-31
US20220071983A1 (en) 2022-03-10
AU2018332191B2 (en) 2021-05-20
RU2020111980A3 (es) 2021-11-23
BR112020004663A2 (pt) 2020-09-15
WO2019053581A1 (en) 2019-03-21
CN111093637A (zh) 2020-05-01
TW201919626A (zh) 2019-06-01
AU2018332191A1 (en) 2020-02-20
JP2020533297A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
AR114930A1 (es) Composición farmacéutica
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
SV2009002857A (es) Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo
AR070158A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
UY32695A (es) FORMA DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL DE UN INHIBIDOR DE LA FAMILIA Bcl-2
MX2021013817A (es) Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
JP2017505293A5 (es)
NI201800071A (es) Compuestos de isoindol
PE20160550A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
AR109652A1 (es) Métodos para utilizar agonistas de fxr
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
UY36123A (es) Derivados de carboxamida
UY36124A (es) Derivados de carboxamida
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
AR084882A1 (es) Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure